Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
The catecholaminergic and serotoninergic neurons in the brain change their performance according to the physiological need via a catecholaminergic/serotoninergic activity enhancer (CAE/SAE) mechanism. Phenylethylamine (PEA), tyramine and tryptamine are the presently known endogenous CAE/SAE substances which enhance the impulse propagation mediated release of catecholamines and serotonin in the brain. A PEA derivative, (-)deprenyl (selegiline), known as a selective inhibitor of MAO-B, is for the time being the only CAE/SAE substance in clinical use. Aiming to develop a selective CAE/SAE substance much more potent than (-)deprenyl, a series of new 1-aryl-2-alkylaminoalkanes, structurally unrelated to PEA and the amphetamines, was designed and prepared. Among them, (-)1-(benzofuran-2-yl)-2-propylaminopentane ((-)BPAP) was selected as a promising candidate substance for further studies. (-)BPAP significantly enhanced in rats the impulse propagation mediated release of catecholamines and serotonin in the brain 30min after acute injection of 0.36nmol/kg sc. In the shuttle box, (-)BPAP was in rats about 130 times more potent than (-)deprenyl in antagonizing tetrabenazine induced inhibition of performance. (+/-)BPAP protected cultured hippocampal neurons from the neurotoxic effect of beta-amyloid in 10(-14)-10(-15)M concentration.
Yoneda
F
F
Research Institute, Fujimoto Pharmaceutical Corporation, Matsubara, Osaka 580-8503, Japan. soyaku@fujimoto-pharm.co.jp
Moto
T
T
Sakae
M
M
Ohde
H
H
Knoll
B
B
Miklya
I
I
Knoll
J
J
D000662:Amphetamines / Q000138:chemical synthesis / Q000494:pharmacology; D000682:Amyloid / Q000032:analysis / Q000037:antagonists & inhibitors; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects; D001572:Benzofurans / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000502:physiology; D001933:Brain Stem / Q000378:metabolism; D002395:Catecholamines / Q000378:metabolism*; D002478:Cells, Cultured; D004558:Electric Stimulation; D006624:Hippocampus / Q000166:cytology; D008995:Monoamine Oxidase / Q000187:drug effects; D009474:Neurons / Q000187:drug effects*; D010627:Phenethylamines / Q000737:chemistry / Q000494:pharmacology; D051381:Rats; D012642:Selegiline / Q000737:chemistry / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism*; D013329:Structure-Activity Relationship; D014363:Tryptamines / Q000494:pharmacology; D014439:Tyramine / Q000494:pharmacology
C404200:1-(benzofuran-2-yl)-2-propylaminopentane; D000662:Amphetamines; D000682:Amyloid; D001572:Benzofurans; D002395:Catecholamines; D010627:Phenethylamines; D014363:Tryptamines; D012642:Selegiline; D012701:Serotonin; C030820:tryptamine; D008995:Monoamine Oxidase; D014439:Tyramine